A Agilent Technologies Inc.

Agilent Deploys Next Generation Explosive Detection System at London Heathrow Airport

(NYSE: A) today announced the deployment of the next generation of alarm resolution technology for checkpoints throughout London Heathrow airport, delivering advanced security and efficiency. The Insight200M from Agilent ensures increased safety on planes while improving passenger experience at airports.

The ban on liquids in carry-on luggage was slowly lifted to allow baby food, medicinal items, and duty-free items, and there is a continuous shift to further simplify the experience at checkpoints while maintaining security. This shift has led to the adoption of new computed tomography X-ray (CT) screening technology in place of conventional X-ray systems. Heathrow has announced the rollout of the new CT security equipment throughout the airport over the next few years, however it requires an advanced alarm resolution system, such as the Insight200M, to be in place after the primary screening to resolve alarms and ensure safety while maintaining passenger satisfaction.

The Insight200M liquid explosive detection system (LEDS) is ECAC standard 3 Type A & B certified and provides cutting-edge technology that works alongside CT systems. It enables increased passenger throughput, as the Insight200M has a low false alarm rate, ensuring that items are screened quickly with the high detection rate.

“As one of the world’s premier travel hubs, Heathrow airport’s deployment of Insight200M systems continues a strong partnership that started with Cobalt Light Systems (now part of Agilent) in 2013,” said Geoff Winkett, vice president and general manager of Molecular Spectroscopy at Agilent. “The new fleet has been deployed at Heathrow throughout the busy summer months with minimal impact to operations due to the dedication of the Agilent and Heathrow teams.”

While the 100 mL rule for liquids will remain in place for all passengers travelling through the UK for the foreseeable future, once CT and Insight200M solutions are deployed, this security solution could potentially end the requirement for passengers to remove liquids and laptops from cabin baggage when passing through security.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated of $6.85 billion in fiscal 2022 and employs 18,000 worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on , , and .

EN
29/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch